These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15580678)

  • 1. Hyperkalemia after the publication of RALES.
    Newsome BB; Warnock DG
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580678
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperkalemia after the publication of RALES.
    Goldfarb DS
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15575065
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperkalemia after the publication of RALES.
    Witham MD; Gillespie ND; Struthers AD
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580679
    [No Abstract]   [Full Text] [Related]  

  • 4. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperkalemia after the publication of RALES.
    Cavallari L; Vaitkus P; Groo V
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580677
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
    Gottlieb S
    BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321896
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD; Gillespie ND; Struthers AD
    Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone use and renal toxicity: population based longitudinal analysis.
    Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
    BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone therapy in heart failure patients with chronic kidney disease.
    Lopes R; Lourenco P; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2009 Oct; 32(10):597. PubMed ID: 19911355
    [No Abstract]   [Full Text] [Related]  

  • 16. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of spironolactone use in ambulatory heart failure patients.
    Kandula P; Shah R
    Clin Cardiol; 2009 Jun; 32(6):347-8. PubMed ID: 19569078
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    Ugeskr Laeger; 2004 Sep; 166(37):3201-3. PubMed ID: 15384373
    [No Abstract]   [Full Text] [Related]  

  • 19. Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
    Harv Heart Lett; 2010 Feb; 20(6):2. PubMed ID: 20376944
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.